Interleukin-4 (IL-4) and IL-13 bind to a shared heterodimeric complex on endothelial cells mediating vascular cell adhesion molecule-1 induction in the absence of the common gamma chain.

Interleukin-4 (IL-4) and IL-13 exert similar, nonadditive effects on endothelial cells, inducing vascular cell adhesion molecule-1 (VCAM-1) expression and subsequent transmigration of eosinophils. The receptor for IL-4 and IL-13 was described as a shared heteromultimeric complex in which the common gamma-chain (gamma c) subunit was essential for activity. Endothelial cell bound both cytokines with high affinity; by flow cytofluorometry and reverse transcription-polymerase chain reaction (RT-PCR), they expressed IL-4 receptor alpha (IL-4R alpha) but did not express the gamma c of the IL-2R. Radioligand cross-linking experiments followed by immunoprecipitation with the monoclonal antibody (MoAb) S697 to the IL-4R alpha showed IL-4-specific binding at 130 kD, the IL-4R alpha, and to a minor extent to a double band coimmunoprecipitated at 65 to 75 kD. [125 I]IL-13 bound predominantly to the 65- to 75- kD band and with a trace amount of binding at 130 kD. However, no ligand-cross-linked receptor was precipitated by the MoAb S697, indicating a cognate novel IL-13-binding subunit. Excess unlabeled IL-4 completely displaced IL-13 binding. Similarly, nonsignaling IL-4 (Y124D)-mutant abolished IL-4- and IL-13-mediated signal transduction. Unlabeled IL-13 competed successfully for IL-4 binding at 65 to 75 kD but was unable to completely displace Il-4 from its binding to the IL-4R alpha. The MoAb TUGh4, specific for the gamma c, failed to precipitate ligand-cross-linked IL-4R and IL-13R. Therefore, the subunit structure of the functional receptors for IL-4 and IL-13 on human endothelial cells does not use or require the common gamma c of the IL-2R.

[1]  V. Casolaro,et al.  Stat6 inhibits human interleukin-4 promoter activity in T cells , 1998 .

[2]  J. Peterson,et al.  Inhibition of Angiogenesis by Interleukin 4 , 1998, The Journal of experimental medicine.

[3]  J. Greve,et al.  An immune cell-selective interleukin 4 agonist. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[4]  I. Adcock,et al.  Interleukin-4 and lipopolysaccharide synergize to induce vascular cell adhesion molecule-1 expression in human lung microvascular endothelial cells. , 1998, American journal of respiratory cell and molecular biology.

[5]  E. Bröcker,et al.  An antagonistic IL-4 mutant prevents type I allergy in the mouse: inhibition of the IL-4/IL-13 receptor system completely abrogates humoral immune response to allergen and development of allergic symptoms in vivo. , 1998, Journal of immunology.

[6]  A. Villa,et al.  Structural and functional basis for JAK3-deficient severe combined immunodeficiency. , 1997, Blood.

[7]  J. Johnston,et al.  Interleukin-4 Signaling in B Lymphocytes from Patients with X-linked Severe Combined Immunodeficiency* , 1997, The Journal of Biological Chemistry.

[8]  A. Mantovani,et al.  Early activation signals in endothelial cells. Stimulation by cytokines. , 1997, Arteriosclerosis, thrombosis, and vascular biology.

[9]  B. Schnyder,et al.  Tumor Necrosis Factor α Enhances the Expression of the Interleukin (IL)-4 Receptor α-Chain on Endothelial Cells Increasing IL-4 or IL-13-induced Stat6 Activation* , 1997, The Journal of Biological Chemistry.

[10]  You-Wen He,et al.  The IL-2 receptor gamma c chain does not function as a subunit shared by the IL-4 and IL-13 receptors. Implication for the structure of the IL-4 receptor. , 1995, Journal of immunology.

[11]  J. Banchereau,et al.  The Primary Binding Subunit of the Human Interleukin-4 Receptor Is Also a Component of the Interleukin-13 Receptor (*) , 1995, The Journal of Biological Chemistry.

[12]  M. Welham,et al.  Interleukin-13 Signal Transduction in Lymphohemopoietic Cells , 1995, The Journal of Biological Chemistry.

[13]  R. Puri,et al.  Receptor for Interleukin 13 , 1995, The Journal of Biological Chemistry.

[14]  J. Pober,et al.  IL-4 induction of VCAM-1 on endothelial cells involves activation of a protein tyrosine kinase. , 1995, Journal of immunology.

[15]  P. Ferrara,et al.  Characterization and Comparison of the Interleukin 13 Receptor with the Interleukin 4 Receptor on Several Cell Types (*) , 1995, The Journal of Biological Chemistry.

[16]  T. Malek,et al.  Expression and function of the gamma c subunit of the IL-2, IL-4, and IL-7 receptors. Distinct interaction of gamma c in the IL-4 receptor. , 1995, Journal of immunology.

[17]  R. Coffman,et al.  IL-13 selectively induces vascular cell adhesion molecule-1 expression in human endothelial cells. , 1995, Journal of immunology.

[18]  A. Duschl,et al.  Both Interleukin 4 and Interleukin 13 Induce Tyrosine Phosphorylation of the 140-kDa Subunit of the Interleukin 4 Receptor (*) , 1995, The Journal of Biological Chemistry.

[19]  M. Seminario,et al.  The role of eosinophils in the pathogenesis of asthma. , 1994, Current opinion in immunology.

[20]  B. Ryffel,et al.  Growth inhibition of human colorectal‐carcinoma cells by interleukin‐4 and expression of functional interleukin‐4 receptors , 1994, International journal of cancer.

[21]  M. Hemler,et al.  The pathophysiologic role of alpha 4 integrins in vivo. , 1994, The Journal of clinical investigation.

[22]  S. Bernasconi,et al.  Regulation of endothelial and mesothelial cell function by interleukin-13: selective induction of vascular cell adhesion molecule-1 and amplification of interleukin-6 production. , 1994, Blood.

[23]  K. Sugamura,et al.  Expression of the IL-2 receptor γ chain on various populations in human peripheral blood , 1994 .

[24]  R. Moser Transendothelial Migration of Eosinophils: Unanswered Questions a , 1994, Annals of the New York Academy of Sciences.

[25]  S. Nishikawa,et al.  Functional participation of the IL-2 receptor gamma chain in IL-7 receptor complexes. , 1994, Science.

[26]  S. Akira,et al.  Cytokine signal transduction , 1994, Cell.

[27]  K. Arai,et al.  Sharing of the interleukin-2 (IL-2) receptor gamma chain between receptors for IL-2 and IL-4. , 1993, Science.

[28]  S. Ziegler,et al.  Interleukin-2 receptor gamma chain: a functional component of the interleukin-7 receptor. , 1993, Science.

[29]  R. de Waal Malefyt,et al.  An interleukin 4 (IL-4) mutant protein inhibits both IL-4 or IL-13- induced human immunoglobulin G4 (IgG4) and IgE synthesis and B cell proliferation: support for a common component shared by IL-4 and IL-13 receptors , 1993, The Journal of experimental medicine.

[30]  C. Heusser,et al.  Interleukin-4 induces tissue eosinophilia in mice: correlation with its in vitro capacity to stimulate the endothelial cell-dependent selective transmigration of human eosinophils. , 1993, The Journal of laboratory and clinical medicine.

[31]  G. Zurawski,et al.  Receptors for interleukin‐13 and interleukin‐4 are complex and share a novel component that functions in signal transduction. , 1993, The EMBO journal.

[32]  A. Minty,et al.  Simultaneous quantitation of cytokine mRNAs in interleukin-1 beta stimulated U373 human astrocytoma cells by a polymerisation chain reaction method involving co-amplification with an internal multi-specific control. , 1992, European cytokine network.

[33]  W. Sebald,et al.  Conversion of human interleukin‐4 into a high affinity antagonist by a single amino acid replacement. , 1992, The EMBO journal.

[34]  L. Olgiati,et al.  Migration of primed human eosinophils across cytokine-activated endothelial cell monolayers. , 1992, Blood.

[35]  H. Asao,et al.  An associated molecule, p64, with IL-2 receptor beta chain. Its possible involvement in the formation of the functional intermediate-affinity IL-2 receptor complex. , 1992, Journal of immunology.

[36]  F. Luscinskas,et al.  IL-4 induces adherence of human eosinophils and basophils but not neutrophils to endothelium. Association with expression of VCAM-1. , 1992, Journal of immunology.

[37]  W. Paul,et al.  The IL-4 receptor: biochemical characterization of IL-4-binding molecules in a T cell line expressing large numbers of receptors. , 1991, Journal of immunology.

[38]  M. Thornhill,et al.  IL-4 increases human endothelial cell adhesiveness for T cells but not for neutrophils. , 1990, Journal of immunology.

[39]  S. Ziegler,et al.  Cloning of the human and murine interleukin-7 receptors: Demonstration of a soluble form and homology to a new receptor superfamily , 1990, Cell.

[40]  M. Elices,et al.  VCAM-1 on activated endothelium interacts with the leukocyte integrin VLA-4 at a site distinct from the VLA-4/Fibronectin binding site , 1990, Cell.

[41]  Alan I. Alpert,et al.  The murine interleukin-4 receptor: Molecular cloning and characterization of secreted and membrane bound forms , 1989, Cell.

[42]  B. Ryffel,et al.  Identification of interleukin 4 receptor‐associated proteins and expression of both high‐ and low‐affinity binding on human lymphoid cells , 1989, European journal of immunology.

[43]  G. Kitas,et al.  Purification of human blood eosinophils by negative selection using immunomagnetic beads. , 1989, Journal of immunological methods.

[44]  B. Schleiffenbaum,et al.  Interleukin 1 and tumor necrosis factor stimulate human vascular endothelial cells to promote transendothelial neutrophil passage. , 1989, The Journal of clinical investigation.

[45]  M. Shibuya,et al.  Genistein, a specific inhibitor of tyrosine-specific protein kinases. , 1987, The Journal of biological chemistry.

[46]  P. Chomczyński,et al.  Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. , 1987, Analytical biochemistry.

[47]  L. Old,et al.  Tumor necrosis factor (TNF). , 1985, Science.

[48]  J. Fehr,et al.  Antiadhesive properties of biological surfaces are protective against stimulated granulocytes. , 1985, The Journal of clinical investigation.

[49]  D Rodbard,et al.  Ligand: a versatile computerized approach for characterization of ligand-binding systems. , 1980, Analytical biochemistry.

[50]  P. Hart,et al.  Involvement of the IL-2 receptor gamma-chain (gammac) in the control by IL-4 of human monocyte and macrophage proinflammatory mediator production. , 1998, Journal of immunology.

[51]  M. Hemler,et al.  The Pathophysiologic Role of a 4 Integrins In Vivo , 2022 .